2003

166. Acton RT, Nabell LM (P4) : Assessing genetic risk of cancer. In: Ellis N (ed), Inherited Cancer, Springer-Verlag, 2003.

167. Ahmed A, Tollefsbol TO (PP) : Telomeres, telomerase and telomerase inhibition: Clinical implications for cancer. J Amer Geriatrics Soc 51:116-122, 2003.

168. Atigadda VR (P1) , Vines KK, Grubbs CJ (P1) , Hill DL (P1) , Beenken SW (CA, P1) , Bland KI (CA) , Brouillette WJ (P1) , Muccio DD (P1) : Conformationally defined retinoic acid analogs. 5. Large-scale synthesis and mammary cancer chemopreventive activity for (2E,4E,6Z,8E)-8-(3',4'-dihydro-1'(2'H)-naphthalen-1'-ylidene)-3,7-dimethyl-2,4,6-octatrienoic acid (9cUAB30). J Med Chem 46:3766-3769, 2003.

169. Barker SD, Coolidge CJ, Kanerva A, Hakkarainen T, Yamamoto M (P4) , Rivera AA, Bhoola SM, Barnes MN, Alvarez RD, Curiel DT (P4) , Hemminki A (CD) : The secretory leukoprotease inhibitor (SLPI) promoter for ovarian cancer gene therapy. J Gene Med 5:300-310, 2003.

170. Barker SD, Dmitriev I (CD) , Nettelbeck DM, Lui B, Rivera AA, Bhoola SM, Barnes MN , Alvarez RD , Curiel DT (P4) , Hemminki A (CD) : Combined transcriptional and transductional targeting improves the specificity and efficacy of adenoviral gene delivery to ovarian carcinoma. Gene Therapy 10:1198-1204, 2003.

171. Beenken SW (CA, P1) , Urist MM, Zhang Y, Desmond RA, Krontiras H (P3, PP, CD) , Medina H, Bland KI (CA) : Axillary lymph node status, but not tumor size, predicts locoregional recurrence and overall survival after mastectomy for breast cancer. Ann Surg 237:732-739, 2003.

172. Bell WC, Myers RB, Oelschlager DK, Hosein T, Grizzle WE (CC) : The response of extracellular signal-regulated kinase (ERK) to androgen induced proliferation in the androgen sensitive prostate cancer cell line, LNCaP. Biotechnic and Histochem 78:11-16, 2003.

173. Belousova N, Korokhov N, Krendelshchikova V, Simonenko V, Mikheeva G, Triozzi PL (P5) , Aldrich WA , Banerjee PT, Gillies SD, Curiel DT (P4) , Krasnykh V (PP) : Genetically targeted adenovirus vector directed to CD40-expressing cells. J Virol 77:11367-11377, 2003.

174. Bland KI (CA) : Failure of routine axillary nodal sampling to predict survival outcomes in lymph node-negative (N0) breast cancer. Ann Surg 237:168-170, 2003.

175. Blume SW, Miller DM, Guarcello V, Shrestha K, Meng Z, Snyder RC, Grizzle WE (CC) , Ruppert J (P3) , Gartland GL, Stockard CR, Jones DE Jr, Emanuel PD: Inhibition of tumorigenicity by the 5'-untranslated RNA of the human c-myc P0 transcript. Exp Cell Res 288:131-142, 2003.

176. Buchsbaum DJ (P5) , Zhou T (P5) , Grizzle WE (CC) , Oliver PG, Hammond CJ, Zhang S, Carpenter DM, LoBuglio AF (P2) : Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model. Clin Cancer Res 9:3731-3741, 2003.

177. Casillas M, Brotherton SL, Andrews LG, Ruppert J (P3) , Tollefsbol TO (PP) : Induction of endogenous telomerase (hTERT) by c-Myc in WI-38 fibroblasts transformed with specific genetic elements. Gene 316:57-65, 2003

178. Casillas MA Jr, Lopatina N, Andrews LG, Tollefsbol TO (PP) : Transcriptional control of the DNA methyltransferases is altered in aging and neoplastically-transformed human fibroblasts. Mol Cell Biochem 252:33-43, 2003.

179. Chaudhuri TR, Cao Z, Krasnykh VN (PP) , Stargel AV, Belousova N, Partridge EE, Zinn KR (CD) : Blood-based screening and light-based imaging for the early detection and monitoring of ovarian cancer xenografts. Technol Cancer Res Treat 2:171-179, 2003.

180. Chhieng DC (CC) , Marley EF, Tabbara SO, Talley LI (PP) , Frost AR (CC, P2, P3) : Microvessel density and vascular endothelial growth factor expression in infiltrating lobular mammary carcinoma. Breast J 9:200-207, 2003.

181. Davila M, Frost AR (CC, P2, P3) , Grizzle WE (CC) , Chakrabarti R: LIM kinase 1 is essential for the invasive growth of prostate epithelial cells: Implications in prostate cancers. J Biol Chem 278:36868-36875, 2003.

182. Forero-Torres A (P5, CD) , Meredith RF (P6) , Khazaeli MB (P6) , Carpenter DM, Shen S (P6) , Thornton J, Schlom J, LoBuglio AF (P2) : A novel monoclonal antibody design for radioimmunotherapy. Cancer, Biotherapy Radiopharm 18:751-760, 2003.

183. Grubbs CJ (P1) , Hill DL (P1) , Bland KI (CA) , Beenken SW (CA, P1) , Lin TH, Eto I, Atigadda VR (P1) , Vines KK, Brouillette WJ (P1) , Muccio DD (P1) : 9cUAB30, an RXR specific retinoid, and/or tamoxifen in the prevention of methylnitrosourea-induced mammary cancers. Cancer Letters 201:17-24, 2003.

184. Hakkarainen T, Hemminki A (CD) , Pereboev A, Barker S, Asiedu C, Strong TV (PP) , Kanerva A, Wahlfors J, Curiel DT (P4) : CD40 is expressed on ovarian cancer cells and can be utilized for targeting adenoviruses. Clin Cancer Res 9:619-624, 2003.

185. Hansen NJ, Poole JC, Andrews LG, Tollefsbol TO (PP) : Telomerase: structure and function. In: Cooper DN (ed), Nature's Encyclopedia of the Human Genome, Nature Publishing Group, London, 5, 478-483, 2003.

186. Harms JF, Welch DR (P2) : MDA-MB-435 human breast carcinoma metastasis to bone. Clin Exp Metastasis 20:327-334, 2003.

187. Harms JF, Welch DR (P2) , Miele ME: KISS1 metastasis suppression and emergent pathways. Clin Exper Metastasis 20:11-18, 2003.

188. Hemminki A (CD) , Kanerva A, Kremer EJ, Bauerschmitz GJ, Smith BF, Liu B, Wang M, Desmond RA, Keriel A, Barnett B, Baker HJ, Siegal GP (CB) , Curiel DT (P4) : A canine conditionally replicating adenovirus for evaluating oncolytic virotherapy in a syngeneic animal model. Mol Ther 7:163-173, 2003.

189. Hemminki A (CD) , Kanerva A, Liu B, Wang M, Alvarez RD , Siegal GP (CB) , Curiel DT (P4) : Modulation of coxsackie-adenovirus receptor expression for increased adenoviral transgene expression. Cancer Res 63:847-853, 2003.

190. Hemminki A (CD) , Wang M, Hakkarainen T, Desmond RA, Wahlfors JJ, Curiel DT (P4) : Production of EGFR targeting molecule from a conditionally replicating adenovirus impairs its oncolytic potential. Cancer Gene Ther 10:583-588, 2003.

191. Huang YZ, Zang M, Xiong WC, Luo Z, Mei L (PP) : Erbin suppresses the MAP kinase pathway. J Biol Chem 278:1108-1114, 2003.

192. Hunter KW, Welch DR (P2) , Liu ET: Genetic background is a major determinant of metastatic potential. Nature Genetics 34:23-24, 2003.

193. Kanerva A, Zinn KR (CD) , Chaudhuri TR, Lam JT, Suzuki K, Uil TG, Hakkarainen T, Bauerschmitz GJ, Wang M, Liu B, Cao Z, Alvarez RD , Curiel DT (P4) , Hemminki A (CD) : Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor targeted oncolytic adenovirus. Mol Ther 8:449-458, 2003.

194. Kawakami Y, Li H, Lam JT, Krasnykh VN (PP) , Curiel DT (P4) , Blackwell JL: Substitution of the adenovirus serotype 5 knob with a serotype 3 knob enhances multiple steps in virus replication. Cancer Res 63:1262-1269, 2003.

195. Kim J, Luo W, Chen DT (CD, PP) , Earley K, Tunstead J, Yu-Lee LY, Lin SH: Antitumor activity of the 16-kDa prolactin fragment in prostate cancer. Cancer Res 63:386-393, 2003.

196. Kirby TO, Curiel DT (P4) , Alvarez RD : Gene therapy for ovarian cancer: Progress and potential. Hematol Oncol Clin North Am 17:1021-1050, 2003.

197. Korokhov N, Mikheeva G, Krendelshchikov A, Belousova N, Simonenko V, Krendelshchikova V, Pereboev A, Kotov A, Kotova O, Triozzi PL (P5) , Aldrich WA , Douglas JT, Lo KM, Banerjee PT, Gillies SD, Curiel DT (P4) , Krasnykh V (PP) : Targeting of adenovirus via genetic modification of the viral capsid combined with a protein bridge. J Virol 77:12931-12940, 2003.

198. Krontiras H (P3, PP, CD) , Bland KI (CA) : When is sentinel node biopsy for breast cancer contraindicated? Surg Oncol 12:207-210, 2003.

199. Lam JT, Bauerschmitz GJ, Kanerva A, Barker SD, Straughn JM, Wang M, Barnes MN , Blackwell JL, Siegal GP (CB) , Alvarez RD , Curiel DT (P4) , Hemminki A (CD) : Replication of an integrin targeted conditionally replicating adenovirus on primary ovarian cancer spheroids. Cancer Gene Ther 10:377-387, 2003.

200. Li M, Ren S, Tilli MT , Flaws J, Lubet R, Grubbs CJ (P1) , Furth PA : Chemoprevention of mammary carcinogenesis in a transgenic mouse model by alpha-difluoromethylnornithine (DFMO) in the diet is associated with decreased cyclin D1 activity. Oncogene 22:2568-2572, 2003.

201. Liu K, Lin FT (CD) , Ruppert J (P3) , Lin WC (CD) : Regulation of E2F1 by BRCT-domain containing protein TopBP1. Mol Cell Biol 23:3287-3304, 2003.

202. Lopatina NG, Poole JC, Saldanha S, Hansen NJ , Key JS, Pita M, Andrews LG, Tollefsbol TO (PP) : Control mechanisms in the regulation of hTERT expression in differentiating human teratocarcinoma cells. Biochem Bioph Res Comm 306:650-659, 2003.

203. Louro ID, Bailey EC, Ruppert J (P3) : Suppression subtractive hybridization for identification and functional analysis of tumor suppressor genes. Methods Mol Biol 222:453-462, 2003.

204. Mahasreshti PJ, Kataram M, Wang MH, Stockard CR, Grizzle WE (CC) , Carey DE, Siegal GP (CB) , Curiel DT (P4) : Intravenous delivery of adenovirus-mediated sFLT-1 results in liver toxicity. Clin Cancer Research 9:2701-2710, 2003.

205. Manni A, Washington S, Craig L, Cloud M, Griffith JW, Verderame MF, Texter LJ, Mauger D, Demers LM, Harms JF, Welch DR (P2) : Effects of alpha-difluoromethylornithine on local recurrence and pulmonary metastasis from MDA-MB-435 breast cancer xenografts in nude mice. Clin Exp Metastasis 20:321-325, 2003.

206. Mastro AM, Gay CV, Welch DR (P2) : The skeleton as a unique environment for breast cancer cells. Clin Exp Metastasis 19:275-284, 2003.

207. Medina-Franco H, Salter M, Beenken SW (CA, P1) , Heslin MJ, Urist MM: Local recurrence after breast conservation therapy for invasive breast cancer: Associated factors and implication in patient management. Revista de Investigacion Clinica ( Mexico ) 5:93-97, 2003.

208. Meehan WJ, Welch DR (P2) : Breast cancer metastasis suppressor 1: Update. Clin Exp Metastasis 20:45-50, 2003.

209. Meredith RF (P6) , Shen S (P6) , Macey D, Khazaeli MB (P6) , Carey DE, Robert F, LoBuglio AF (P2) : Comparison of biodistribution, dosimetry and outcome from clinical trials of radionuclide-CC49 antibody therapy. Cancer Biotherapy 18:393-404, 2003.

210. Merrell M, Suarez-Cuervo C, Harris KW (PP) , Vaananen HK, Selander K: Bisphosphonate induced growth inhibition of breast cancer cells is augmented by p38 inhibition. Breast Cancer Res Treat 81:231-241, 2003.

211. Ohtsuka T, Buchsbaum DJ (P5) , Oliver P, Makhija S, Kimberly RP, Zhou T (P5) : Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway. Oncogene 22:2034-2044, 2003.

212. Poulin N, Guillaud M, Urban DA, Kelloff J, Beenken SW (CA, P1) , Grizzle WE (CC) : Risk biomarker evaluation for chemoprevention trials: The utility of nuclear morphometry on thin tissue sections. Analytical Cell Path 25:129-138, 2003.

213. Rodriguez-Burford C (CC) , Oelschlager DK, Talley LI (PP) , Barnes MN , Partridge EE, Grizzle WE (CC) : The use of dimethyl sulfoxide (DMSO) as a vehicle in cell culture experiments using ovarian carcinoma cell lines. J Biotech & Histoch 78:17-21, 2003.

214. Rogers BE, Chaudhuri TR, Reynolds PN, Della Manna D, Zinn KR (CD) : Non-invasive gamma camera imaging of gene transfer using an adenoviral vector encoding an epitope-tagged receptor as a reporter. Gene Ther 10:105-114, 2003.

215. Safavy A, Bonner JA, Waksal HW, Buchsbaum DJ (P5) , Gillespie GY, Khazaeli MB (P6) , Arani RB, Chen DT (CB, PP) , Carpenter DM, Raisch KP: Synthesis and biological evaluation of paclitaxel-C225 conjugate as a model for targeted drug delivery. Bioconjug Chem 14:302-310, 2003.

216. Saldanha S, Andrews LG, Tollefsbol TO (PP) : Analysis of telomerase activity and detection of its catalytic subunit, hTERT. Analytical Biochem 315:1-21, 2003.

217. Saldanha SN, Andrews LG, Tollefsbol TO (PP) : Assessment of telomere length and factors that contribute to its stability. Eur J Biochem 270:389-403, 2003.

218. Samanta M, Harkins L, Klemm K, Britt WJ, Cobbs CS (CD) : High prevalence of human cytomegalovirus in prostatic intraepithelial neoplasia and prostatic carcinoma. J Urol 170:998-1002, 2003.

219. Seales EC, Jurado GA , Singhal A, Bellis SL (P3) : Ras oncogene directs expression of a differentially sialylated, functionally altered beta1 integrin. Oncogene 22:7137-7145, 2003.

220. Shevede-Samant L (PP) , Welch DR (P2) : Metastasis suppressor pathways - an evolving paradigm. Cancer Letters 198:1-3, 2003.

221. Suarez Cuervo C, Harris KW (PP) , Kallman L, Vaananen HK, Selander K: Tumor necrosis factor alpha induced interleukin-6 production requires ERK1 activation in breast cancer cells. Breast Cancer Res Treat 80:71-78, 2003.

222. Takayama K, Reynolds PN, Short JJ, Kawakami Y, Adachi Y, Glasgow JN, Rots MG, Krasnykh VN (PP) , Douglas JT, Curiel DT (P4) : A mosaic adenovirus possessing serotype Ad5 and serotype Ad3 knobs exhibits expanded tropism. Virology 309:282-293, 2003.

223. Uil TG, Seki T, Dmitriev I (CD) , Kashentseva E, Douglas JT, Rots MG, Middeldorp JM, Curiel DT (P4) : Generation of an adenoviral vector containing an addition of a heterologous ligand to the serotype 3 fiber knob. Cancer Gene Ther 10:121-124, 2003.

224. Wang-Johanning F, Frost AR (CC, P2, P3) , Jian B, Epp L, Lu DW, Johanning GL: Quantitation of HERV-K env gene expression and splicing in human breast cancer. Oncogene 22:1528-1535, 2003.

225. Welch DR (P2) , Harms JF, Mastro AM, Gay CV, Donahue HJ: Breast cancer metastasis to bone: Research challenges and opportunities. J Musculoskeletal Neuronal Interactions 3:30-38, 2003.

226. Welch DR (P2) , Hunter KW: A new member of the growing family of metastasis suppressors identified in prostate cancer. J Natl Cancer 95:839-841, 2003.

227. Wu L, Wu Y, Gathings B, Wan M, Li X, Grizzle WE (CC) , Liu Z, Lu C, Mao Z, Cao X: Smad4 as a transcription corepressor for estrogen receptor alpha. J. Biol Chem 278:15192-15200, 2003.

228. Xu Y, Szalai AJ, Zhou T (P5) , Zinn KR (CD) , Chaudhuri TR, Li X, Koopman WJ, Kimberly RP: FcgammaRs modulate cytotoxicity of anti-Fas antibodies: Implications for agonistic antibody-based therapeutics. J Immunol 171:562-568, 2003.

229. Yamamoto M (P4) , Davydova J, Takayama K, Alemany R, Curiel DT (P4) : Transcription initiation activity of adenovirus left-end sequence in adenovirus vectors with e1 deleted. J Virol 77:1633-1637, 2003.

230. Yamamoto M (P4) , Davydova J, Wang M, Siegal GP (CB) , Krasnykh VN (PP) , Vickers SM, Curiel DT (P4) : Infectivity enhanced cyclooxygenase-2 promoter-based conditionally replicative adenovirus for pancreatic cancer. Gastroenterology 125:1203-1218, 2003.

231. Zhang HG, Grizzle WE (CC) : Aging, immunity, and tumor susceptibility. Immunol Allergy Clin N Am 23:83-102, 2003.

232. Zinn KR (CD) , Chaudhuri TR, Stargel AV, Kumar S, Ponnazhagan S: Gamma camera imaging of Tc-99m-labeled AAV vector followed by bioluminescence imaging of luciferase transgene expression. Mol Ther 7:S184, 2003.